Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Avstera Therapeutics Corp. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to GOMEZ RODRIGUEZ, JULIO WASHINGTON, who is the busiest examiner with 1 pending action. The prosecution is concentrated in 1 distinct examiner and 1 distinct art unit. This suggests a focused technical scope for the company's current activity in the Biotechnology & Pharmaceuticals sector.
Because the portfolio contains only 1 distinct art unit, practitioners should tailor their arguments to the specific standards of that unit. GOMEZ RODRIGUEZ, JULIO WASHINGTON is the sole distinct examiner, meaning his individual tendencies will impact the outcome of the 1 pending office action. The company's reliance on 1 distinct examiner across 1 distinct art unit indicates a centralized prosecution strategy. Successfully navigating the 1 pending office action is critical, as it represents the entirety of the company's active workload in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18515479 | mRNA COMPOSITION FOR PREVENTING AND TREATING CANCER | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18515479 | mRNA COMPOSITION FOR PREVENTING AND TREATING CANCER | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §103§112DP | Non-Final OA | — | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAvstera Therapeutics Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Julio Washington Gomez Rodriguez has the most, with 1 of Avstera Therapeutics Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
